Dermata Therapeutics, Inc.
Disclosed SEC business address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO, CA, 92130
Dermata Therapeutics, Inc. (ticker DRMA, CIK 0001853816) is tracked by Global Barry from its public SEC filings and disclosures. Disclosed industry classification: Pharmaceutical Preparations (SIC 2834). Disclosed business address country: United States. Every item is grounded on the cited public source — no figures are fabricated.
Full evidence detail
Company deep views this month: 2 of 5.
Filing intelligence
50 filings ingested; deep FILING ANALYSIS shown for 8 filings.
- FACT Only one ingested version of this accession exists; no intra-document revisions have been observed. Change tracking for this filing requires ≥2 ingested versions. 2026-08-17 source ↗
- ANALYSIS This 8-K was filed 6 days after the previous ingested 8-K (2026-08-11). 11 filings of this type are ingested. 2026-08-17 source ↗
- UNKNOWN Changed risk-factor language (Item 1A): not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2026-08-17 source ↗
- UNKNOWN MD&A highlights: not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2026-08-17 source ↗
- UNKNOWN Material business developments: not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2026-08-17 source ↗
- UNKNOWN Debt / capital-structure changes: not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2026-08-17 source ↗
- UNKNOWN Acquisitions / divestitures: not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2026-08-17 source ↗
- UNKNOWN Litigation / regulatory matters: not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2026-08-17 source ↗
Latest developments
Most recent SEC filing events ingested for this company (newest first).
- FACT S-3 filed 2026-10-09 source ↗
- FACT 4 filed (period 2025-08-16) 2026-08-18 source ↗
- FACT 4 filed (period 2026-08-16) 2026-08-18 source ↗
- FACT 8-K filed (period 2026-08-16) 2026-08-17 source ↗
- FACT 10-Q filed (period 2026-06-30) 2026-08-11 source ↗
- FACT 8-K filed (period 2026-08-11) 2026-08-11 source ↗
- FACT 8-K filed (period 2026-08-05) 2026-08-05 source ↗
- FACT 4 filed (period 2026-06-16) 2026-06-16 source ↗
- FACT S-8 filed 2026-06-04 source ↗
- FACT SCHEDULE 13D filed 2026-06-01 source ↗
Insider ownership filings
17 insider ownership filings (Forms 3/4/5) ingested (metadata level).
Geographic footprint (disclosed)
Geographic footprint limited to locations disclosed in ingested evidence.
- FACT Principal executive office (disclosed): SAN DIEGO, CA, 92130
- FACT Mailing address (disclosed): SAN DIEGO, CA, 92130
- FACT State/country of incorporation (disclosed): DE
Industry classification (disclosed)
Industry classification as disclosed by the issuer's SEC record.
- FACT Primary industry (disclosed SIC): Pharmaceutical Preparations (SIC 2834)
- FACT SEC filer category: <br>Emerging growth company
Supply chain
No supplier or customer relationships are disclosed in ingested evidence. Supply-chain relationships are shown only when explicitly disclosed and cited; undisclosed relationships are never inferred.
- UNKNOWN No supplier or customer relationships are disclosed in ingested evidence. Supply-chain relationships are shown only when explicitly disclosed and cited; undisclosed relationships are never inferred.
Risk factors
Risk-factor language requires ingested filing document bodies.
- UNKNOWN Risk-factor language requires ingested filing document bodies.
Sources
- U.S. Securities and Exchange Commission, EDGAR · filing document · retrieved 2026-11-02T10:51:47.846119+00:00
- U.S. Securities and Exchange Commission, EDGAR · filing document · retrieved 2026-11-02T10:51:51.866715+00:00
- U.S. Securities and Exchange Commission, EDGAR · filing document · retrieved 2026-11-02T10:51:56.089439+00:00
- U.S. Securities and Exchange Commission, EDGAR · filing document · retrieved 2026-11-02T10:51:45.836337+00:00
Grounded on public SEC filings and disclosures with explicit evidence tiers and citations. This page is informational only and is not investment advice. No figures are fabricated; unavailable data is shown as unavailable.